

People

Appointments

Eric Dadey appointed VP of Drug Delivery at Atrix

Atrix Laboratories (<http://www.atrixlabs.com>) has announced the promotion of Eric Dadey to Vice President of Drug Delivery. Dadey joined Atrix's R&D team in December 2000 as a senior project leader, and was promoted to Director of Drug Delivery in August 2002.

Prior to his tenure at Atrix, Dadey served as Assistant Professor of Pharmaceutics College of Pharmacy at the University of Illinois. Earlier, he held the position of pharmaceutical scientist/group leader at Nycomed Salutar and a similar position with Access. Dadey also holds several patents for various polymer-based drug delivery technologies.

Steve Warren, VP of R&D at Atrix, said: '...Eric will continue to lead Atrix forward as we further explore innovative uses for the Atrigel technology.'

Atrix Laboratories is an emerging pharma company specializing in drug delivery and is currently developing a diverse range of proprietary products, including those for oncology, pain management and dermatology.

Amgen appoints David R. Parkinson to VP and Head of Clinical Oncology

Amgen (<http://www.amgen.com>) have announced the appointment of David R. Parkinson to the position of VP and Head of the Clinical Oncology Therapeutic Area. Parkinson joins Amgen from Novartis, where he was most recently Global Head, Translational Development.

Parkinson will direct global development efforts in oncology for new product candidates and new indications for marketed products at Amgen. He brings to the company a wealth of experience in drug development, and an international reputation in clinical oncology, including a track record in developing new therapies in oncology.

Beth C. Seidenberg, Senior VP of Amgen Development and Chief Medical Officer, said: 'Amgen is striving to expand its supportive care platform as well as develop novel therapeutics to treat cancer. Parkinson will be a valuable leader in that quest.'

Parkinson's career includes Assistant Professor at Tufts University School of Medicine, two years at the University of Texas MD Anderson Cancer Center, then he joined the Cancer Therapy Evaluation Program at the National Cancer Institute.

Prabhavathi Fernandes appointed to Supervisory Board of GPC Biotech

GPC Biotech (<http://www.gpc-biotech.com>) have announced the appointment of Prabhavathi Fernandes to their Supervisory Board. Fernandes has over 25 years of experience in drug discovery and development.

Bernd R. Seizinger, President and Chief Executive Officer of GPC Biotech, said: 'We are delighted to have Fernandes join our Supervisory Board. Her extensive scientific knowledge and keen business acumen have enabled her throughout her career to turn scientific ideas into commercial opportunities.'

Fernandes most recently served as CEO of Ricerca Biosciences. Prior to joining Ricerca, Fernandes was a founder and CEO of Molecule Therapeutics, before which she worked for many years at major pharma companies, including a position as VP, Biomolecular Screening Drug Discovery at Bristol-Myers Squibb.

On her appointment, Fernandes said: '...This is certainly an exciting time for the company as it moves its lead compound, satraplatin, into Phase III clinical trials. I look forward to assisting GPC Biotech in any way I can'.

Kosan appoints Charles Homcy to Board of Directors

Kosan Biosciences (<http://www.kosan.com>) has appointed Charles Homcy to its Board of Directors, where he will serve as a member of the Strategic Advisory to the Board. Homcy currently serves as senior advisor and member of the Board at Millenium Pharmaceuticals.

Danile V. Santi, Chairman and CEO of Kosan, commented: 'The addition of Homcy to the Board of Directors reflects Kosan's commitment to achieving the highest level of scientific and operational excellence. Charles' knowledge and experience will be of immense benefit to Kosan as we enter into an advanced phase as a biotechnology business.'

New CEO at Spherics: Ze'ev Shaked

Ze'ev Shaked has been appointed as Chief Executive Officer and member of the Board of Directors at Spherics (<http://www.spherics.com>), where he will head the management team, which includes the President David Ensore.

Shaked brings over 20 years of executive management experience in building, finances and managing biotech and pharma organizations. Prior to joining Spherics, he was Chief Operating Officer of Ilex Oncology and, previously, President of Ilex Products.

Ben Bronstein, a member of Spherics' Board of Directors, said: 'Shaked has a long and outstanding track record in the development of protein therapeutics...His wealth of experience will be invaluable in building a pipeline of products around Spherics' two innovative drug delivery systems...'

Spherics has developed several complementary technologies for non-invasive drug delivery and has established two distinct drug delivery systems; PIN-NanoSpheres and MacroSpheres.

David Ludvigson appointed Executive VP at Nanogen

Nanogen (<http://www.nanogen.com>), a leading provider of molecular diagnostics, has announced changes in its senior management, with the appointment of David Ludvigson, an existing board member, as Executive Vice President. Also announced was the departure of VP and CFO Gerard A. Willis, who is leaving to pursue other opportunities.

Howard Birndorf, Nanogen's Chairman and CEO, said: 'Nanogen is striving to accelerate growth and establish itself as a leader in the emerging molecular diagnostics field. David's... experience in developing and managing high growth businesses and in corporate development, will be important to our success.'

Ludvigson has a broad range of management and financial experience in both biopharma and technology companies, including a position as CFO and COO at Matrix Pharmaceuticals, and VP and CFO for IDEC Pharmaceuticals.

People was written by
Joanne Clough